What’s next for Antisense Therapeutics?

Mark Diamond, CEO and Managing Director of Australian biotech company Antisense Therapeutics (ASX: ANP), discusses the firm’s latest goings-on with Share Cafe’s Tim McGowen.

Key points in the video:
  • details of ANP’s recent $A7.6m capital raising and how it plans to use the money
  • what the company’s share registry looks like post this placement
  • 2021 and what it holds for Antisense
  • the company’s plans with regard to overseas listings
Tim McGowen

About Tim McGowen

Tim McGowen is the co-founder of informedinvestor.com.au. He was previously the founder of Fortitude Capital the Hedge fund of the Year in 2008 & 2009. More recently he was a global Portfolio Manager for PM Capital.

View more articles by Tim McGowen →